Racura Oncology Ltd
RAC
Company Profile
Business description
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
Contact
1 Macquarie Place
Level 36
Gateway
SydneyNSW2000
AUST: +61 280513043
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.
stocks
Wide moat airport share steps up its investments
Profits flatten as airport ramps up redevelopment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,314.90 | 7.40 | 0.08% |
| CAC 40 | 8,484.43 | 31.34 | 0.37% |
| DAX 40 | 26,136.56 | 153.52 | 0.59% |
| Dow JONES (US) | 53,277.01 | 517.80 | 0.98% |
| FTSE 100 | 10,816.56 | 68.40 | 0.64% |
| HKSE | 25,491.12 | 518.34 | -1.99% |
| NASDAQ | 26,180.46 | 113.29 | 0.43% |
| Nikkei 225 | 65,962.29 | 54.07 | -0.08% |
| NZX 50 Index | 13,929.83 | 42.83 | -0.31% |
| S&P 500 | 7,674.37 | 33.21 | 0.43% |
| S&P/ASX 200 | 9,102.30 | 9.10 | 0.10% |
| SSE Composite Index | 3,891.35 | 13.85 | -0.35% |